

A-1016 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
The First Train-of-Four Twitch Response as Predictor of Cisatracurium Reversal Time Hans Kirkegaard-Nielsen, MD; James E. Caldwell, MB; Tom Heier, MD, Department of Anesthesia, UCSF, San Francisco, CA, United States. T1 is a good predictor of cisatracurium reversal time, if the endpoint of reversal is TOF ratio 0.70. However, if the target TOF ratio is 0.90, T1 is a poor predictor of reversal time.

A-1017 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Dose-Response and Onset/Offset Characteristics of Rapacuronium Aaron F. Kopman, M.D.; Monika M. Klewicka, B.A.; Frank Flores, M.D.; Khurram Gbori, M.D.; George G. Neuman, MD, Anesthesiology, Saint Vincents Hospital & Medical Center, New York, NY, United States. We found rapacuronium to be more potent than previously described, with an ED95 of 0.80 mg/kg. Its onset profile is similar to succinylcholine.

A-1018 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Are There Stereospecific Effects of Atracurium and Cisatracurium on Mast Cell Activation in Human Skin? Wolfgang Koppert, MD; James A. Blunk, MD; Lars J. Petersen, MD; Reinhard Sittl, MD; Martin Schmelz, MD, Department of Anesthesiology, University of Erlangen, Erlangen, Germany. Stereospecific effects of atracurium and cisatracurium were found for efficacy, but not potency of mast cell activation.

A-1019 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Conformational Mechanism of Actions of Gallamine Chingmuh Lee, M.D.; Thomas Jones, Ph.D., Anesthesiology, UCLA Med Sch and Tripos, Los Angeles, St. Louis, United States. Gallamine has many rotatable bonds, but limited conformational variability. Distance of 10.98–12.36 [angstrom] N-to-N explains neuromuscular block; of 4.21–4.45 [angstrom] N to vdw extension of O explains tachycardia.

A-1020 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Dose-Response Study of Succinylcholine in Subjects Treated with Bambuterol Hanne Lippert, MD; Ulla Bang, MD, Department of Anesthesia, Aarhus University Hospital, Aarhus N, Denmark. In patients treated with bambuterol 2 hours before anaesthesia, succinylcholine 0.25–0.5 mg/kg allowed easy intubation within one minute with a 2.5 times prolongation of the neuromuscular block.

A-1021 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Patient Tailored Infusion of Cisatracurium during General Anesthesia Mohammad Maroof, MD; T.J. Gan, MD; W.S. York, MD; A. Monnig, BSN, Anesthesiology, University of North Carolina, Chapel Hill, NC, United States. A steady state of relaxation and timely reversal is achieved by infusion of cisatracurium calculated by the individual patient's response to the intubating dose of the relaxant.

A-1022 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Cisatracurium - Results from a Post-Marketing Surveillance Study in Germany Hermann Mellinghoff; Mabir Uslu; Christoph Diefenbach; Thomas Meuser, Dept. of Anesthesiology, University of Cologne, Koeln, Germany. 2951 patients in German hospitals who had received cisatracurium were studied to determine the intubating conditions as well as the incidence of adverse events.

A-1023 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Effect of Priming Intervals on the Onset of Cisatracurium Neuromuscular Blockade Johann Motsch, MD; Anja Beilbarz; Matthias Bock, MD; Bernd W. Bottiger, MD; Eike O. Martin, MD, Department of Anesthesiology, University Hospital Heidelberg, Heidelberg, Germany. A priming interval of 60 sec accelerates cisatracurium onset, but > 180 sec increases the risk of partial nm-blockade.

A-1024 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Outcome Evaluation of Patients after Muscle Biopsy for Malignant Hyperthermia Testing Rainer Mueller, MD; Martin Anetseder, MD; Andreas Hoyer, MD; Edmund Hartung, MD, PhD; Norbert Roewer, MD, PhD, Dep. of Anesthesiology, University, Wuerzburg, Germany. Physical handicap, pain and time off work for about 10 days are common problems affecting patients after muscle biopsy for Malignant Hyperthermia testing.

A-1025 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Sepsis Attenuates the Neuromuscular Blocking Effects of d-Tubocurarine on Laryngeal Muscles by Presynaptic Mechanism Kobki Nishikawa, MD; Eiichi Narimatsu, MD; Akiyoshi Namiki, MD, Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan. Sepsis-induced attenuation in the neuromuscular blocking effects of dTc on laryngeal muscles

A-1026 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Potency of New Muscle Relaxants on Recombinant Muscle-Type Acetylcholine Receptors Matthias Paul, M.D.; Christoph H. Kindler, M.D.; Mark J. Dressler, M.S.; Spencer Yost, M.D., Department of Anesthesia, University of California, San Francisco, CA, United States. Using the *Xenopus* oocyte model for muscle-type acetylcholine receptors Rocuronium was shown to be more potent than Rapacuronium.

A-1027 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
New Method To Neuromuscular Block Monitoring Josep Rodiera, M.D. Ph.D.; Jose Rodriguez-Paz, M.D.; Luis Aliaga, M.D. Ph.D.; Esther Santacana, M.D., Department of Anesthesia, Centro Medico Teknon, Barcelona, Spain. SUMMARY: This study seeks to evaluate a new method of monitoring the neuromuscular block, based on the blood pressure cuff; and to test the capacity of the new method to measure the level of block.

A-1028 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Onset of the Neuromuscular Block at Orbicularis Occuli: Visual Estimation Versus Accelerography Velislav Slavov, MD; Cyrus Motamed, MD; Inanna Gabriel, MD; Gilles Dbonneur, MD; Philippe Duvaldestin, MD, Dept of Anesthesiology, Henri Mondor University Hospital, Creteil, France

A-1029 Room I, 10/16/2000 2:00 PM - 4:00 PM (PS)
Increased Plasma Binding Increases Onset Time Rocuronium Blockade in Rats Carlos Wilkerson, M.D., Ph.D; Joanne Vesce, B.Sc; Donna Geathers, Anesthesiology, Jefferson Medical College, Philadelphia, PA, United States. Addition of α -1-acid glycoprotein (AAG) increases onset time of neuromuscular blockade by 20% following a rocuronium bolus when compared to controls for all 6 rats.